Literature DB >> 16177329

An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin.

Nam-Kyu Lim1, Jung-Hwan Kim, Mee Sook Oh, Sangyoon Lee, Se-Yeon Kim, Keun-Soo Kim, Hyun-Jung Kang, Hyo Jeong Hong, Kyung-Soo Inn.   

Abstract

Lethal factor (LF) is a component of anthrax lethal toxin (LeTx). We generated anti-LF murine monoclonal antibodies (MAbs) that show LeTx-neutralizing activity in vitro and in vivo. Anti-LF MAbs were generated by immunization with recombinant LF, and the MAbs showing LeTx-neutralizing activity in vitro were selected. Two MAbs with the highest affinities, 5B13B1 (dissociation constant [K(d)], 2.62 nM) and 3C16C3 (K(d), 8.18 nM), were shown to recognize the same or closely overlapping epitopes on domain III of LF. The 50% inhibitory concentration of 5B13B1 (0.21 microg/ml) was approximately one-third that of 3C16C3 (0.63 microg/ml) in the in vitro LeTx-neutralization assay. The 5B13B1 antibody, which had the highest neutralizing activity, provided perfect protection against LeTx challenge in an in vivo LeTx neutralization assay using Fisher 344 rats. In addition, the antibody showed pre- and postexposure prophylactic effects in the animal experiments. This is the first report that an MAb binding to domain III of LF has neutralizing activity against LeTx. The 5B13B1 antibody may be useful in prophylaxis against anthrax poisoning.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16177329      PMCID: PMC1230968          DOI: 10.1128/IAI.73.10.6547-6551.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Crystal structure of the anthrax lethal factor.

Authors:  A D Pannifer; T Y Wong; R Schwarzenbacher; M Renatus; C Petosa; J Bienkowska; D B Lacy; R J Collier; S Park; S H Leppla; P Hanna; R C Liddington
Journal:  Nature       Date:  2001-11-08       Impact factor: 49.962

Review 2.  Antitoxins: novel strategies to target agents of bioterrorism.

Authors:  G Jonah A Rainey; John A T Young
Journal:  Nat Rev Microbiol       Date:  2004-09       Impact factor: 60.633

3.  Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.

Authors:  B M Price; A L Liner; S Park; S H Leppla; A Mateczun; D R Galloway
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

4.  Passive transfer of protection against Bacillus anthracis infection in a murine model.

Authors:  R J Beedham; P C Turnbull; E D Williamson
Journal:  Vaccine       Date:  2001-08-14       Impact factor: 3.641

Review 5.  Anthrax.

Authors:  M Mock; A Fouet
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

6.  Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.

Authors:  S F Little; B E Ivins; P F Fellows; A M Friedlander
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

7.  A new epitope tag from hepatitis B virus preS1 for immunodetection, localization and affinity purification of recombinant proteins.

Authors:  Mee Sook Oh; Keun Soo Kim; Young Kug Jang; Cheol Young Maeng; Soon Hong Min; Myeong Hee Jang; Sun Ok Yoon; Jung Hee Kim; Hyo Jeong Hong
Journal:  J Immunol Methods       Date:  2003-12       Impact factor: 2.303

8.  Involvement of domain II in toxicity of anthrax lethal factor.

Authors:  Xudong Liang; John J Young; Sherrie A Boone; David S Waugh; Nicholas S Duesbery
Journal:  J Biol Chem       Date:  2004-10-01       Impact factor: 5.157

9.  Contribution of individual toxin components to virulence of Bacillus anthracis.

Authors:  C Pezard; P Berche; M Mock
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

10.  Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed.

Authors:  Ritsuko Sawada-Hirai; Ivy Jiang; Fei Wang; Shu Man Sun; Rebecca Nedellec; Paul Ruther; Alejandro Alvarez; Diane Millis; Phillip R Morrow; Angray S Kang
Journal:  J Immune Based Ther Vaccines       Date:  2004-05-12
View more
  29 in total

1.  Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.

Authors:  Arnold Louie; Brian D Vanscoy; Henry S Heine; Weiguo Liu; Terry Abshire; Kari Holman; Robert Kulawy; David L Brown; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Neutralizing monoclonal antibody to edema toxin and its effect on murine anthrax.

Authors:  Lisa Winterroth; Johanna Rivera; Antonio S Nakouzi; Ekaterina Dadachova; Arturo Casadevall
Journal:  Infect Immun       Date:  2010-04-12       Impact factor: 3.441

Review 3.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

4.  A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection.

Authors:  Catherine E Vrentas; Mahtab Moayeri; Andrea B Keefer; Allison J Greaney; Jacqueline Tremblay; Danielle O'Mard; Stephen H Leppla; Charles B Shoemaker
Journal:  J Biol Chem       Date:  2016-08-18       Impact factor: 5.157

5.  Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel.

Authors:  Darrell E Singer; Rachel Schneerson; Christian T Bautista; Mark V Rubertone; John B Robbins; David N Taylor
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

6.  Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.

Authors:  Melissa L Nguyen; Sherry R Crowe; Sridevi Kurella; Simon Teryzan; Brian Cao; Jimmy D Ballard; Judith A James; A Darise Farris
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

7.  Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding.

Authors:  Zhaochun Chen; Mahtab Moayeri; Huaying Zhao; Devorah Crown; Stephen H Leppla; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-27       Impact factor: 11.205

Review 8.  Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.

Authors:  Anette Schneemann; Marianne Manchester
Journal:  Future Microbiol       Date:  2009-02       Impact factor: 3.165

9.  In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.

Authors:  Herman F Staats; S Munir Alam; Richard M Scearce; Shaun M Kirwan; Julia Xianzhi Zhang; William M Gwinn; Barton F Haynes
Journal:  Infect Immun       Date:  2007-08-20       Impact factor: 3.441

10.  Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays.

Authors:  Mary Ann Pohl; Johanna Rivera; Antonio Nakouzi; Siu-Kei Chow; Arturo Casadevall
Journal:  Infect Immun       Date:  2013-03-18       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.